Evaluation of Dose-Related Effects of Aspirin on Platelet Function
Top Cited Papers
- 26 June 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 115 (25) , 3156-3164
- https://doi.org/10.1161/circulationaha.106.675587
Abstract
Background— The antiplatelet effect of aspirin is attributed to platelet cyclooxygenase-1 inhibition. Controversy exists on the prevalence of platelet resistance to aspirin in patients with coronary artery disease and effects of aspirin dose on inhibition. Our primary aim was to determine the degree of platelet aspirin responsiveness in patients, as measured by commonly used methods, and to study the relation of aspirin dose to platelet inhibition. Methods and Results— We prospectively studied the effect of aspirin dosing on platelet function in 125 stable outpatients with coronary artery disease randomized in a double-blind, double-crossover investigation (81, 162, and 325 mg/d for 4 weeks each over a 12-week period). At all doses of aspirin, platelet function was low as indicated by arachidonic acid (AA)-induced light transmittance aggregation, thrombelastography, and VerifyNow. At any 1 dose, resistance to aspirin was 0% to 6% in the overall group when AA was used as the agonist, whereas it was 1% to 27% by other methods [collagen and ADP-induced light transmittance aggregation, platelet function analyzer (PFA-100)]. Platelet response to aspirin as measured by collagen-induced light transmittance aggregation, ADP-induced light transmittance aggregation, PFA-100 (81 mg versus 162 mg, P ≤0.05), and urinary 11-dehydrothromboxane B 2 was dose-related (81 mg versus 325 mg, P =0.003). No carryover effects were observed. Conclusions— The assessment of aspirin resistance is highly assay-dependent; aspirin is an effective blocker of AA-induced platelet function at all doses, whereas higher estimates of resistance were observed with methods that do not use AA as the stimulus. The observation of dose-dependent effects despite nearly complete inhibition of AA-induced aggregation suggests that aspirin may exert antiplatelet properties through non–cyclooxygenase-1 pathways and deserves further investigation.Keywords
This publication has 27 references indexed in Scilit:
- Polymorphisms of COX-1 and GP VI associate with the antiplatelet effect of aspirin in coronary artery disease patientsThrombosis and Haemostasis, 2006
- Aspirin resistance in secondary stroke preventionActa Neurologica Scandinavica, 2005
- Resistance to antiplatelet drugs: current status and future researchExpert Opinion on Pharmacotherapy, 2005
- Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastographyJournal of Thrombosis and Haemostasis, 2005
- Screening for Aspirin Responsiveness After Transient Ischemic Attack and StrokeStroke, 2005
- Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarctionThe American Journal of Cardiology, 2005
- Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of PlateletsCirculation, 2005
- Biological Assessment of Aspirin Efficacy on Healthy IndividualsStroke, 2005
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy SubjectsJournal of Clinical Investigation, 1982